Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route

Infection and Immunity

Volumn 66, Issue 12, 1998, Pages 5743-5750

  Power, Carl A ^a   Wei, Guojian ^a   Bretscher, Peter A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELPER CELL; IMMUNIZATION; IMMUNOBLOTTING; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING; TUBERCULOSIS;

EID: 0031740995     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.12.5743-5750.1998     Document Type: Article

References (44)

1. Bretscher, P. A. 1996. Quantitative considerations in the design of vaccination strategies against pathogens uniquely susceptible to cell-mediated attack, p. 187-204. In S. H. E. Kaufmann (ed.), Concepts in vaccine development. Walter de Gruyter, Berlin, Germany.
2. Bretscher, P. A. 1974. Hypothesis. On the control between cell-mediated, IgM and IgG immunity. Cell. Immunol. 13:171-195.
3. Bretscher, P. A. 1979. In vitro induction of delayed-type hypersensitivity. Eur. J. Immunol. 9:311-316.
4. Bretscher, P. A. 1991. The regulatory functions of CD4+ and CD8+ T-cell subsets in immune class regulation. Res. Immunol. 142:45-49.
5. Bretscher, P. A. 1981. Significance and mechanisms of cellular regulation of the immune response. Fed. Proc. 40:1473-1478.
6. Bretscher, P. A. 1992. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immunol. Today 13:342-345.
7. Bretscher, P. A., G. Wei, J. N. Menon, and H. Beilefeldt-Ohmann. 1992. Establishment of stable cell mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257:539-542.
8. Cherwinski, H. M., J. H. Schumacher, K. D. Brown, and R. R. Mosmann. 1987. Two types of helper T cell clones. III. Further differences in lymphokine synthesis between TH1 and TH2 clones revealed by RNA hybridization, functionally monospecific bioassays and monoclonal antibodies. J. Exp. Med. 166:1229-1244.
9. Coffman, R. L., and T. R. Mosmann. 1991. CD4+ T cell subsets: regulation of differentiation and function. Res. Immunol. 142:7-8.
10. Czerkinsky, C., G. Andersson, H. P. Ekre, L. K. Nilsson, L. Klareskog, and O. Ouchterlony. 1988. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 110:29-36.
11. Ellner, J. J. 1989. Tuberculosis, p. 647-664. In W. N. Kelley (ed.), Textbook of internal medicine. J. B. Lippincott, Philadelphia, Pa.
12. Familletti, P. C., S. Rubinstein, and S. Pestka. 1981. A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol. 78:387-394.
13. Fine, P. E. M. 1988. BCG vaccination against tuberculosis and leprosy. Br. Med. Bull. 44:691-704.
14. Frieden, T. R., T. Sterling, A. Paldos-Meider, T. O. Kilburn, G. M. Cauthen, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328:521-526.
15. Gros, P., E. Skamene, and A. Forget. 1981. Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. J. Immunol. 127:2417-2421.
16. Hernandez-Pando, R., L. Pavon, K. Arriaga, H. Orozco, V. Madrid-Marina, and G. A. W. Rook. 1997. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect. Immun. 65:3317-3327.
17. Hornbeck, P. 1994. Antibodies, p. 2.1.2-2.1.20. In J. E. Colligan, A. Kruisbeck, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
18. Howard, J. G. 1988. Immunological regulation and control of experimental leishmaniasis. Int. Rev. Exp. Pathol. 28:79-116.
19. Hu-Li, J., J. Ohara, C. V. Watson, W. Tsang, and W. E. Paul. 1989. Derivation of a T cell line that is highly responsive to IL4 and IL2 (CT.4R) and of an hyporesponsive mutant of that cell line (CT.4S). J. Immunol. 142:800-807.
20. Klinman, D. M., and T. B. Nutman. 1994. ELISPOT assay to detect cytokine-secreting murine and human cells, p. 6.16.1-6.19.6. In J. E. Colligan, A. Kruisbeck, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons Inc., New York, N.Y.
21. Lagrange, P. H., G. B. Mackaness, and T. E. Miller. 1974. Influence of dose and route of antigen injections on the immunological induction of T cells. J. Exp. Med. 139:528-542.
22. Lehn, M., W. Y. Weiser, S. Engelhorn, S. Gillis, and H. G. Remold. 1989. IL4 inhibits hydrogen peroxide production and anti-leishmanial capacity of human cultured monocytes mediated by IFN-gamma. J. Immunol. 143:3020-3024.
23. Liew, F. Y., and J. G. Howard. 1982. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific effector T cells. J. Immunol. 128:1917-1922.
24. Locksley, R. M., and P. Scott. 1991. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol. Today 12(3): A58-A61.
25. + T-helper-cell responses in mice with low-level Candida albicans infections. Infect. Immun. 64:4907-4914.
26. Menon, J. N., and P. A. Bretscher. 1996. Characterization of the immunological memory state generated in mice "susceptible" to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge. Eur. J. Immunol. 26:243-249.
27. Menon, J. N., and P. A. Bretscher. Parasite dose determines the Th1/Th2 nature of the response to Leishmania major independently of infection route, strain of host or of parasite. Eur. J. Immunol., in press.
28. North, R. J., and A. A. Izzo. 1993. Mycobacterial virulence. Virulent strains of Mycobacterium tuberculosis have faster in vivo doubling times and are better equipped to resist the growth inhibiting functions of specific immunity. J. Exp. Med. 177:1723-1733.
29. Ohara, J., and W. E. Paul. 1985. Production of a monoclonal antibody to and molecular characterisation of B-cell stimulatory factor-1. Nature 315:333-336.
30. Orme, I. M., and F. M. Collins. 1983. Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J. Exp. Med. 158:74-83.
31. Parish, C. R. 1972. The relationship between humoral and cell-mediated immunity. Transplant. Rev. 13:35-66.
32. Pearson, R. D., D. A. Wheeler, L. H. Harrison, and H. D. Kay. 1983. The immunobiology of leishmaniasis. Rev. Infect. Dis. 5:907-927.
33. Power, C. A., et al. Unpublished data.
34. Ramshaw, I. A., P. A. Bretscher, and C. R. Parish. 1976. Regulation of the immune response. I. Suppression of delayed-type hypersensitivity by T cells from mice expressing humoral immunity. Eur. J. Immunol. 6:674-679.
35. Ramshaw, I. A., I. F. C. McKenzie, P. A. Bretscher, and C. R. Parish. 1976. Discrimination of suppressor T cells of humoral and cell-mediated immunity by anti-Ly and anti-Ia sera. Cell. Immunol. 31:364.
36. Rosenthal, S. R. 1980. Vaccines other than BCG used against tuberculosis, p. 14-34. In S. R. Rosenthal (ed.), BCG vaccine: tuberculosis-cancer. PSG Publishing Inc., Littleton, Mass.
37. Salvin, S. B. 1958. Occurrence of DTH during the development of Arthus type sensitivity. J. Exp. Med. 107:109-124.
38. Schurr, E., D. Malo, D. Radzioch, E. Buschman, K. Morgan, P. Gros, and E. Skamene. 1991. Genetic control of innate resistance to mycobacterial infections. Immunol. Today 12(3):A42-A45.
39. Sher, A., R. T. Gazzinelli, I. P. Oswald, M. Clerici, M. Kullberg, E. J. Pearce, J. A. Berzovsky, T. R. Mosman, S. L. James, H. C. Morse, and G. M. Shearer. 1992. Role of T-cell derived cytokines in the down regulation of immune responses in parasitic and retroviral infections. Immunol. Rev. 127:183-204.
40. Surcel, H. M., M. Troye-Blomberg, S. Paulie, G. Andersson, C. Moreno, G. Pasvol, and J. Ivanyi. 1994. Th1/Th2 profiles in tuberculosis, based upon proliferation and the cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81:171-176.
41. ten Dam, H. G. 1984. Research on BCG vaccination. Adv. Tuberc. Res. 21: 79-106.
42. Titus, R. G., B. Sherry, and A. Cerami. 1989. Tumor necrosis factor plays a protective role in experimental murine leishmaniasis. J. Exp. Med. 170:2097-2104.
43. Turk, J. L., and A. D. M. Bryceson. 1971. Immunological phenomena in leprosy and related diseases. Adv. Immunol. 13:209-266.
44. Wortis, H. H., R. B. Taylor, and D. W. Dresser. 1966. Antibody production studied by means of the LHG assay. I. The splenic response of CBA mice to sheep erythrocytes. Immunology 11:663-669.